Access cutting-edge alzheimer's disease treatment through this clinical trial at a research site in Indianapolis. Study-provided care at no cost to qualified participants.
Access alzheimer's disease specialists in Indianapolis at no cost
This study follows strict safety protocols and ethical guidelines
All study-related alzheimer's disease treatment provided free
This is an open label study to treat dominantly inherited Alzheimer's disease (DIAD) mutation carrier participants from the DIAN-TU-001 gantenerumab Open Label Extension (OLE) period with lecanemab to determine the effects of amyloid removal on age of onset and clinical progression compared to external controls, if amyloid plaque as measured by amyloid PET can be fully removed in DIAD, and the effects of amyloid removal on biomarkers of disease progression.
Sponsor: Washington University School of Medicine
Check if you qualify for this alzheimer's disease clinical trial in Indianapolis, IN
If you're searching for alzheimer's disease treatment options in Indianapolis, IN, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Indianapolis research site is actively enrolling participants for this clinical trial. You'll receive care from experienced alzheimer's disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.